<sec id="s1"><title>Introduction</title><p>Melioidosis is a serious infectious disease caused by the environmental Gram-negative bacillus <italic>Burkholderia pseudomallei</italic>. The organism is distributed in soil across much of southeast Asia and northern Australia <xref rid="pone.0054961-Limmathurotsakul1" ref-type="bibr">[1]</xref>, and infection results from bacterial inoculation, ingestion or inhalation of the organism. The majority of cases are reported during the rainy season in northeast Thailand and northern Australia, and the most common presenting features are community-acquired pneumonia and/or bacteraemia <xref rid="pone.0054961-Limmathurotsakul1" ref-type="bibr">[1]</xref>. The spectrum of clinical manifestations is very diverse, and melioidosis may present as acute, chronic and latent disease. Patients with chronic melioidosis may present with signs, symptoms and chest radiograph changes that are indistinguishable from tuberculosis <xref rid="pone.0054961-Limmathurotsakul1" ref-type="bibr">[1]</xref>.</p><p>Comparisons have also been drawn between melioidosis and tuberculosis based on apparent parallels in epidemiology, pathophysiology and therapy. Melioidosis and tuberculosis have risk factors in common, in that corticosteroid use and diabetes predispose to both diseases <xref rid="pone.0054961-Limmathurotsakul1" ref-type="bibr">[1]</xref>. At clinical presentation, chronic melioidosis, like tuberculosis, causes chronic suppurative lesions that do not respond to commonly used first line antimicrobials (viz., aminopenicillins, first and second generation cephalosporins, macrolides or aminoglycosides). Histological examination of tissue taken from patients with melioidosis may reveal granulomas with central necrosis, which mimic those of tuberculosis <xref rid="pone.0054961-Wong1" ref-type="bibr">[2]</xref>. At a cellular level, both <italic>B. pseudomallei</italic> and <italic>Mycobacterium tuberculosis</italic> are intracellular pathogens and this ability to parasitise cells appears crucial to their virulence <xref rid="pone.0054961-Wiersinga1" ref-type="bibr">[3]</xref>, <xref rid="pone.0054961-Collins1" ref-type="bibr">[4]</xref>. Melioidosis, like tuberculosis, is also able to cause latent infection, the longest documented interval between exposure and clinical melioidosis being 62 years <xref rid="pone.0054961-Limmathurotsakul1" ref-type="bibr">[1]</xref>.</p><p>While chronic melioidosis is clinically similar to active tuberculosis, and latent of forms of both melioidosis and tuberculosis undoubtedly occur, acute melioidosis has no clinical counterpart in tuberculosis. Only &#x0223c;10% of melioidosis cases are chronic (symptoms &#x0003e;2 months) <xref rid="pone.0054961-Limmathurotsakul1" ref-type="bibr">[1]</xref>, and the majority of melioidosis cases present acutely, with sepsis frequently complicated by hypotension and organ dysfunction, which rarely occurs in tuberculosis. Acute melioidosis is therefore a clinical entity quite distinct from tuberculosis. In northeast Thailand, mortality is 40% despite appropriate treatment <xref rid="pone.0054961-Koh1" ref-type="bibr">[5]</xref>, whereas tuberculosis mortality is &#x0003c;2% with appropriate treatment. HIV infection is also an important risk factor for tuberculosis, but there is no established association between HIV and melioidosis <xref rid="pone.0054961-Chierakul1" ref-type="bibr">[6]</xref>. The taxonomic relationship between <italic>B. pseudomallei</italic> and <italic>M. tuberculosis</italic> is distant (they are in different phyla: Proteobacteria and Actinobacteria, respectively). Their cell surfaces also present different pathogen-associated molecular patterns (PAMP) to the host immune system, and it seems reasonable to expect the host to respond differently to challenge by different PAMPs.</p><p>In this study, we sought differences in host response between acute melioidosis and tuberculosis using whole genome arrays to compare gene expression in circulating peripheral blood leukocytes collected from two cohorts of patients, one with melioidosis and one with tuberculosis. We also sought to define whether whole blood gene expression profiling distinguishes between melioidosis and tuberculosis.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><p>The melioidosis data were taken from a previously published cohort of 30 patients and 30 healthy controls, frequency-matched for diabetes and glibenclamide use (an oral hypoglycaemic drug used to treat diabetes mellitus) <xref rid="pone.0054961-Koh1" ref-type="bibr">[5]</xref>. Each group contained 10 non-diabetics and 20 diabetics. Diabetics were divided into 10 taking glibenclamide (&#x0200a;=&#x0200a;glyburide) and 10 not taking any sulphonylurea (but who may have been on insulin, metformin or diet-control alone). We adjusted for diabetes and glibenclamide because two-thirds of all melioidosis patients have diabetes, diabetes is itself a pro-inflammatory condition, and because glibenclamide is anti-inflammatory <xref rid="pone.0054961-Koh1" ref-type="bibr">[5]</xref>. The tuberculosis cohort has been published previously and consists of 20 patients with pulmonary tuberculosis and 24 healthy controls <xref rid="pone.0054961-Berry1" ref-type="bibr">[7]</xref>. That study did not control for the effect of confounders such as diabetes. Inclusion and exclusion criteria for both studies have been published previously <xref rid="pone.0054961-Koh1" ref-type="bibr">[5]</xref>, <xref rid="pone.0054961-Berry1" ref-type="bibr">[7]</xref>. Eligible cases for both studies were persons aged between 18 and 75 years. In the melioidosis cohort, diabetes was defined as an abnormal Hb A<sub>1c</sub> at enrolment or a previous diagnosis of diabetes. The tuberculosis cohort excluded patients with diabetes. Both studies excluded patients who were pregnant or immunosuppressed.</p><sec id="s2a"><title>Melioidosis Microarrays</title><p>The methods used in the melioidosis cohort have been reported previously <xref rid="pone.0054961-Koh1" ref-type="bibr">[5]</xref> and the data is deposited at ArrayExpress, EMBL-EBI (accession number E-TABM-852-n). In brief, a 3 ml blood sample was collected from each study subject in a PaxGene&#x02122; Blood RNA tube (PreAnalytiX, GmbH) and stored at &#x02013;70&#x000b0;C. RNA was extracted using the PaxGene&#x02122; Blood RNA Purification Kit (PreAnalytix) according to the manufacturer&#x02019;s instructions. The RNA was amplified using the Illumina&#x000ae; TotalPrep RNA Amplification Kit (Applied Biosystems) and assayed using the Illumina&#x000ae; HumanWG-6 v3.0 Expression BeadChip (Illumina&#x000ae;), which probes 48,803 transcripts from across the human genome. Quantitative PCR verification of these microarrays has been reported previously <xref rid="pone.0054961-Koh1" ref-type="bibr">[5]</xref>.</p></sec><sec id="s2b"><title>Tuberculosis Microarrays</title><p>The methods used in the tuberculosis cohort have been published elsewhere previously <xref rid="pone.0054961-Berry1" ref-type="bibr">[7]</xref>. In brief, a 3 ml blood sample was collected into Tempus tubes (Applied Biosystems, California) and stored at &#x02013;20 to &#x02013;80&#x000b0;C. RNA was extracted using the PerfectPure RNA Blood Kit (5 PRIME) according to the manufacturer&#x02019;s instructions. The RNA was then amplified using the Illumina CustomPrep RNA amplification kit (Applied Biosystems) and assayed using the Illumina Human HT-12 v3 BeadChip array (Illumina), which uses the same probe set as the HumanWG-6 v3.0. Raw data was downloaded from a publicly available repository (NCBI GEO accession number GSE19491) and consists of tuberculosis patients with controls recruited in London. The study also included data from a cohort of South African tuberculosis patients, but that cohort was excluded from this analysis because it does not contain uninfected controls, which made it impossible to normalize across the cohorts. The original study was analysed using GeneSpring, but we reanalysed the raw data using Bioconductor for the sake of comparability.</p></sec><sec id="s2c"><title>Ethics</title><p>Approval for the melioidosis study was obtained from the Oxford Tropical Research Ethics Committee (OXTREC 018-07) and the Ethics Committee of the Faculty of Tropical Medicine, Mahidol University (MUTM 2008-001-01) <xref rid="pone.0054961-Koh1" ref-type="bibr">[5]</xref>. Approval for the tuberculosis study was obtained from the Research Ethics Committee at St Mary&#x02019;s Hospital, London, UK (REC 06/Q0403/128) <xref rid="pone.0054961-Berry1" ref-type="bibr">[7]</xref>. Written informed consent was obtained from all subjects.</p></sec><sec id="s2d"><title>Statistical Methods</title><p>Differential expression analyses were performed using Bioconductor <xref rid="pone.0054961-Gentleman1" ref-type="bibr">[8]</xref> version 2.12.1 running on R 2.13.0 <xref rid="pone.0054961-R1" ref-type="bibr">[9]</xref>. Pre-processing was performed using the beadarray 2.2.0 package <xref rid="pone.0054961-Dunning1" ref-type="bibr">[10]</xref>, <xref rid="pone.0054961-Cairns1" ref-type="bibr">[11]</xref>, and background correction was performed using normexp <xref rid="pone.0054961-Ritchie1" ref-type="bibr">[12]</xref>, <xref rid="pone.0054961-Silver1" ref-type="bibr">[13]</xref>. Fluorescence intensities were quantile-normalized between arrays within each cohort and non-expressed probes were removed (detection <italic>p</italic>-value &#x0003e;0.05). Differential expression was performed using limma 3.8.1 <xref rid="pone.0054961-Smyth1" ref-type="bibr">[14]</xref>. For the melioidosis cohort, the linear model fit was log <italic>e</italic>&#x0200a;=&#x0200a;<italic>&#x003b2;</italic>
<sub>0</sub> + <italic>&#x003b2;</italic>
<sub>1</sub>
<italic>x</italic>
<sub>1</sub> + <italic>&#x003b2;</italic>
<sub>2</sub>
<italic>x</italic>
<sub>2</sub> + <italic>&#x003b2;</italic>
<sub>3</sub>
<italic>x</italic>
<sub>3</sub> + <italic>&#x003b2;</italic>
<sub>12</sub>
<italic>x</italic>
<sub>1</sub>
<italic>x</italic>
<sub>2</sub>, where <italic>e</italic> is expression, <italic>x</italic>
<sub>1</sub> is melioidosis, <italic>x</italic>
<sub>2</sub> is diabetes and <italic>x</italic>
<sub>3</sub> is glibenclamide treatment. The expression values for melioidosis, <italic>&#x003b2;</italic>
<sub>1</sub>, are therefore adjusted for diabetes and glibenclamide treatment. For the tuberculosis data, the model was log <italic>e</italic>&#x0200a;=&#x0200a;<italic>&#x003b2;</italic>
<sub>0</sub> + <italic>&#x003b2;</italic>
<sub>1</sub>
<italic>x</italic>
<sub>1</sub>, where <italic>x</italic>
<sub>1</sub> is tuberculosis. The <italic>p</italic>-value cut-off of 0.01 was set following visual inspection of the histogram of unadjusted <italic>p</italic>-values for <italic>&#x003b2;</italic>
<sub>1</sub>, as calculated from the moderated <italic>t</italic>-statistic (B-statistic) using Bayesian methods <xref rid="pone.0054961-Smyth1" ref-type="bibr">[14]</xref>. Illumina probe IDs were mapped to HUGO gene symbols <xref rid="pone.0054961-Bruford1" ref-type="bibr">[15]</xref> by illuminaHumanv3.db <xref rid="pone.0054961-BarbosaMorais1" ref-type="bibr">[16]</xref>. Networks were clustered by pathway by the Reactome <xref rid="pone.0054961-Matthews1" ref-type="bibr">[17]</xref> functional interaction network <xref rid="pone.0054961-Wu1" ref-type="bibr">[18]</xref> plug-in for Cytoscape 2.8.1 <xref rid="pone.0054961-Shannon1" ref-type="bibr">[19]</xref>, restricting the analysis to modules larger than 10 proteins. The <italic>p</italic>-values reported are for the hypergeometric test. The top 1000 probes were used to construct networks for presentation in figures. We searched specifically for interferon-regulated gene signatures on Interferome also <xref rid="pone.0054961-Samarajiwa1" ref-type="bibr">[20]</xref>. Heat maps were drawn with gplots 2.8.0 <xref rid="pone.0054961-Warnes1" ref-type="bibr">[21]</xref> using colour blind-safe colour ramps generated by RColorBrewer 1.0&#x02013;2 <xref rid="pone.0054961-Neuwirth1" ref-type="bibr">[22]</xref>, <xref rid="pone.0054961-Brewer1" ref-type="bibr">[23]</xref>. We divided controls and patients by unsupervised <italic>k</italic>-means <xref rid="pone.0054961-Hartigan1" ref-type="bibr">[24]</xref> and verified stability of the clusters under 5 random starts.</p></sec></sec><sec id="s3"><title>Results</title><p>The melioidosis cohort consisted of 30 patients and 30 controls. Baseline characteristics are in <xref ref-type="table" rid="pone-0054961-t001">Table 1</xref>. In the melioidosis cohort, 6,755 probes were differentially expressed (that is, either up or downregulated) representing 4632 unique genes. Annotation was available for 1,658 of these genes, of which 651 were upregulated and 1,007 were downregulated. The tuberculosis cohort consisted of 20 patients and 24 controls. In the tuberculosis cohort, 6911 probes differentially expressed (5045 unique genes). Annotation was available for 1985 of these genes, of which 847 were upregulated and 1138 were downregulated. In both the melioidosis and the tuberculosis cohorts, the signature seen was dominated by neutrophils, which formed the bulk of the circulating leukocytes. Multiple lymphocyte-related pathways were downregulated, but this reflects the fact that lymphocyte counts were low in both melioidosis and tuberculosis. Pathways associated with transcription and translation were also prominent, in keeping with the large number of genes differentially regulated in both melioidosis and tuberculosis.</p><table-wrap id="pone-0054961-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0054961.t001</object-id><label>Table 1</label><caption><title>Patient characteristics.</title></caption><alternatives><graphic id="pone-0054961-t001-1" xlink:href="pone.0054961.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">Melioidosis patients</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">No diabetes</td><td colspan="2" align="left" rowspan="1">Diabetes patients</td></tr><tr><td align="left" rowspan="1" colspan="1">Parameter</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">On Gb</td><td align="left" rowspan="1" colspan="1">Not on Gb</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Male gender</td><td align="left" rowspan="1" colspan="1">9 of 10</td><td align="left" rowspan="1" colspan="1">6 of 10</td><td align="left" rowspan="1" colspan="1">5 of 10</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">51</td></tr><tr><td align="left" rowspan="1" colspan="1">Glucose (mg dL<sup>&#x02013;1</sup>)</td><td align="left" rowspan="1" colspan="1">128</td><td align="left" rowspan="1" colspan="1">218</td><td align="left" rowspan="1" colspan="1">256</td></tr><tr><td align="left" rowspan="1" colspan="1">Hb A<sub>1c</sub> (%)</td><td align="left" rowspan="1" colspan="1">6.0</td><td align="left" rowspan="1" colspan="1">10.8</td><td align="left" rowspan="1" colspan="1">11.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Neutrophils (&#x000d7;10<sup>9</sup> L<sup>&#x02013;1</sup>)</td><td align="left" rowspan="1" colspan="1">8.1</td><td align="left" rowspan="1" colspan="1">10.8</td><td align="left" rowspan="1" colspan="1">8.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Lymphocytes (&#x000d7;10<sup>9</sup> L<sup>&#x02013;1</sup>)</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.6</td><td align="left" rowspan="1" colspan="1">1.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Mortality</td><td align="left" rowspan="1" colspan="1">1 of 10</td><td align="left" rowspan="1" colspan="1">2 of 10</td><td align="left" rowspan="1" colspan="1">5 of 10<xref ref-type="table-fn" rid="nt101">a</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">
<bold>Controls</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>No diabetes</bold>
</td><td colspan="2" align="left" rowspan="1">
<bold>Diabetes patients</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Parameter</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>On Gb</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Not on Gb</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Male gender</td><td align="left" rowspan="1" colspan="1">10 of 10</td><td align="left" rowspan="1" colspan="1">3 of 10</td><td align="left" rowspan="1" colspan="1">5 of 10</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">54</td><td align="left" rowspan="1" colspan="1">56</td></tr><tr><td align="left" rowspan="1" colspan="1">Glucose (mg dL<sup>&#x02013;1</sup>)</td><td align="left" rowspan="1" colspan="1">95</td><td align="left" rowspan="1" colspan="1">126</td><td align="left" rowspan="1" colspan="1">124</td></tr><tr><td align="left" rowspan="1" colspan="1">Neutrophils (&#x000d7;10<sup>9</sup> L<sup>&#x02013;1</sup>)</td><td align="left" rowspan="1" colspan="1">4.0</td><td align="left" rowspan="1" colspan="1">4.7</td><td align="left" rowspan="1" colspan="1">5.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Lymphocytes (&#x000d7;10<sup>9</sup> L<sup>&#x02013;1</sup>)</td><td align="left" rowspan="1" colspan="1">1.9</td><td align="left" rowspan="1" colspan="1">4.4</td><td align="left" rowspan="1" colspan="1">5.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Hb A<sub>1c</sub> (%)</td><td align="left" rowspan="1" colspan="1">5.4</td><td align="left" rowspan="1" colspan="1">9.0</td><td align="left" rowspan="1" colspan="1">9.0</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label>a</label><p>One patient in this group was lost to follow-up following discharge from hospital, and was counted as having survived to discharge.</p></fn><fn id="nt102"><label/><p>Gb&#x0200a;=&#x0200a;Glibenclamide. Values reported are means, except where stated.</p></fn></table-wrap-foot></table-wrap><sec id="s3a"><title>Pathway Analysis</title><p>Interferon-mediated responses were the dominant pathway seen in both melioidosis and in tuberculosis (<italic>p</italic>&#x0003c;0.0001 for both, <xref ref-type="table" rid="pone-0054961-t002">Tables 2</xref> &#x00026; <xref ref-type="table" rid="pone-0054961-t003">3</xref>). Class 1 and class 2 interferons were prominent in both (<xref ref-type="table" rid="pone-0054961-t004">Table 4</xref>). Of the immune-related pathways, TRAIL (TNF superfamily member 10), tumour necrosis factor &#x003b1; (TNF&#x003b1;), transforming growth factor &#x003b2; (TGF-&#x003b2;), interleukin (IL)-1, IL-2, IL-12, chemokine and Toll-like receptor (TLR) pathways were all differentially regulated (<xref ref-type="table" rid="pone-0054961-t002">Tables 2</xref> &#x00026; <xref ref-type="table" rid="pone-0054961-t003">3</xref>). There was no gene signature that distinguished melioidosis from tuberculosis, and for each of the pathways differentially expressed in melioidosis, we were able to find a counterpart in tuberculosis (<xref ref-type="table" rid="pone-0054961-t002">Tables 2</xref> &#x00026; <xref ref-type="table" rid="pone-0054961-t003">3</xref>). Berry et al. reported an 86-gene signature that was specific for tuberculosis <xref rid="pone.0054961-Berry1" ref-type="bibr">[7]</xref>. This 86-gene signature was also present in melioidosis (<xref ref-type="fig" rid="pone-0054961-g001">Figure 1</xref>).</p><fig id="pone-0054961-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0054961.g001</object-id><label>Figure 1</label><caption><title>The 86-gene signature of tuberculosis is also seen in melioidosis.</title><p>These heat maps demonstrate the gene expression profiles for two cohorts: (A) melioidosis and (B) tuberculosis. The 86 genes displayed are those identified by Berry <italic>et al.</italic>
<xref rid="pone.0054961-Berry1" ref-type="bibr">[7]</xref> as being specific for tuberculosis, after excluding genes differentially regulated in other infections (<italic>Staphylococcus aureus</italic> and Group A Streptococcus) and inflammatory conditions (adult onset Still&#x02019;s disease and systemic lupus erythematosus). Each column in the heat map is the gene expression profile of an individual, with control subjects on the left and patients on the right. Each cell within the heat map is the expression of a single gene: orange genes are upregulated and purple genes are downregulated, with expression normalized across the rows. We used this 86-gene signature to cluster study participants into two groups (marked black and red in the coloured banner at the top of each heat map). In the tuberculosis cohort, three controls clustered with the patients, and two patients clustered with the controls. In the melioidosis cohort, the same 86-gene signature also allowed us to distinguish controls and patients, with the exception of four patients who clustered with the controls. Despite the same microarray platform being used, the two cohorts were assayed as separate batches, so the absolute fluorescence intensities are different, making a direct comparison of melioidosis and tuberculosis impossible. All patients were therefore compared to their own controls.</p></caption><graphic xlink:href="pone.0054961.g001"/></fig><table-wrap id="pone-0054961-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0054961.t002</object-id><label>Table 2</label><caption><title>Genes upregulated in melioidosis and tuberculosis, arranged by pathway.</title></caption><alternatives><graphic id="pone-0054961-t002-2" xlink:href="pone.0054961.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">Melioidosis (total&#x0200a;=&#x0200a;651)</td><td colspan="3" align="left" rowspan="1">Tuberculosis (total&#x0200a;=&#x0200a;847)</td></tr><tr><td align="left" rowspan="1" colspan="1">Pathway</td><td align="left" rowspan="1" colspan="1">Genes</td><td align="left" rowspan="1" colspan="1">List</td><td align="left" rowspan="1" colspan="1">
<italic>p</italic>-value</td><td align="left" rowspan="1" colspan="1">Genes</td><td align="left" rowspan="1" colspan="1">List</td><td align="left" rowspan="1" colspan="1">
<italic>p</italic>-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">IFN-&#x003b3; pathway</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">MEF2A, SLC9A1, IL4R, LYN, SLC3A2, TXN, PML, MKNK1, CDKN2B, RALB, IL1B, JUNB, DDIT3, COL1A2, FGR, TFE3, VDR, ATF6, CDKN1A, FES, MAX, CASP1, PPP2R2A, CEBPB, HCK, JAK2, JAK3, STAT5A, STAT5B, LAMC1, PPARG, PTEN, GADD45G, GADD45B, GADD45A, MAP3K11, FKBP1A, ZBTB17, BCL6, CSNK1A1, YWHAB, STAT1, MAPK13, MAPK14, SOCS3, SOCS1, GRB2, ITGB3, RUNX1, PTPN6, PTPN2, EIF4E, SAP30, IFNGR1, PRKCD, TNF, XIAP, MAP3K3, IL2RG, IRF7, IRF1</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">79</td><td align="left" rowspan="1" colspan="1">MEF2A, MAP3K7, MAP3K8, MAPK1, MAPK3, DUSP10, ARG1, LYN, SLC3A2, TXN, GSK3B, RALB, IL1B, ARRB2, ATF6, CDKN1A, MAX, CASP1, PKN1, CEBPB, PARP14, PPARG, PTEN, RBBP4, RAB5A, YWHAZ, FKBP1A, BCL6, CSNK1A1, YWHAB, YWHAH, DYNLRB1, GRB2, ITGB3, RAP1A, PRKCD, MAP3K3, CAMK2D, NUP153, IRF7, IRF1, CTNNB1, TGFBR2, PML, PPP2CA, SOS1, PPP2CB, DAB2, JUNB, DDIT3, FGR, VDR, TRAF6, ZFYVE16, NCOA2, PPM1A, NR3C1, NEDD4L, JAK2, LAMC1, CREBBP, RHEB, GADD45G, GADD45B, GADD45A, HBP1, STAT1, MAPK14, SOCS3, SOCS1, ELK4, PTPN2, SAP30, PAK2, IFNGR1, EGR3, EGR2, DAPK1, PPP1R15A</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Glypican network</td><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">MEF2A, NFKBIB, NFKBIA, ARF1, SLC9A1, NOD2, LYN, SLC3A2, TXN, PML, MKNK1, DAPP1, CDKN2B, RALB, RELB, JUNB, DDIT3, COL1A2, ARFGAP1, FGR, TFE3, MDK, VDR, VAV1, ATF6, CDKN1A, CDC42, MAX, CASP9, PPP2R2A, REL, CEBPB, HCK, LAMC1, ASAP1, GOSR2, PPARG, NFKB2, PTEN, GADD45G, GADD45B, GADD45A, FKBP1A, ZBTB17, CSNK1A1, YWHAB, MAPK13, MAPK14, PAG1, ERC1, GRB2, RUNX1, PTPN6, EIF4E, SAP30, PRKCD, TNF, XIAP, MAP3K3, IRF7</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">87</td><td align="left" rowspan="1" colspan="1">APP, ARRB2, ASAP1, ATF6, BCL10, BCL3, BIRC2, CASP9, CDC42, CDKN1A, CEBPB, CLTA, CREBBP, CSNK1A1, CTNNB1, DAB2, DAPP1, DDIT3, DUSP10, DYNLRB1, EGR2, EGR3, ELK4, FBXW11, FGR, FKBP1A, FZD1, GADD45A, GADD45B, GADD45G, GOSR2, GRB2, GSK3B, HBP1, HSP90AA1, IRF7, JUNB, LAMC1, LYN, MACF1, MAP3K3, MAP3K7, MAP3K8, MAPK1, MAPK14, MAPK3, MAX, MEF2A, NCOA2, NEDD4L, NFKBIA, NFKBIB, NR3C1, NRAS, NUP153, PAG1, PAK2, PKN1, PML, PPARG, PPM1A, PPP1R15A, PPP2CA, PPP2CB, PRKCD, PTEN, PTPRC, RAB5A, RALB, RAP1A, RBBP4, RELB, RHEB, RIPK2, SAP30, SLC3A2, SOS1, TGFBR2, TNFAIP3, TRAF6, TXN, UBE2D3, VDR, YWHAB, YWHAH, YWHAZ, ZFYVE16</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">TRAIL (TNF superfamily,member 10) signalling</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">NFKBIB, NFKBIA, ARF1, ASAH1, NOD2, LYN, SLC3A2, MKNK1, DAPP1, RELB, FADD, JUNB, ARFGAP1, FGR, VAV1, CDKN1A, TNFSF10, CASP4, CASP9, CASP7, CASP1, LIMK1, REL, HCK, SMPD1, KRT18, LMNB1, ASAP1, GOSR2, PPARG, NFKB2, PTEN, FKBP1A, CSNK1A1, YWHAB, MAPK14, PAG1, MAP4K4, ERC1, GRB2, PTPN6, EIF4E, PRKCD, CTSD, TNF, XIAP, CASP10</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">MAP3K7, APP, MAP3K8, MAPK1, MAPK3, NFKBIB, NFKBIA, ASAH1, LYN, AIFM1, SLC3A2, NRAS, GSK3B, BCL10, RELB, ARRB2, EGF, CDKN1A, CASP4, CASP9, CASP7, CASP8, CASP1, CASP2, CYCS, NSMAF, LMNB1, GOSR2, PPARG, PTEN, BID, YWHAZ, FKBP1A, BCL3, CSNK1A1, YWHAB, BIRC2, YWHAH, PDGFA, GRB2, UBE2D3, RAP1A, CLTA, PRKCD, DAPP1, SOS1, FBXW11, CRADD, JUNB, TNFAIP3, FGR, TRAF6, TNFSF10, LIMK1, RB1, VIM, SMPD1, ASAP1, CREBBP, RHEB, TNFRSF10C, MAPK14, PAG1, RIPK2, EGR3, HSP90AA1, EGR2, CTSD, PTPRC, CASP10</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma membrane estrogen receptor signalling</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">MEF2A, ROCK2, CTNNA1, PLAUR, GRB10, ARF1, SLC9A1, LNPEP, LYN, SLC3A2, MKNK1, EXOC6, EXOC5, TRIP10, GNA13, GNA15, RALB, JUNB, DDIT3, VAMP3, ARFGAP1, FGR, ATF6, RHOQ, SH2B2, CEBPB, HCK, ACAP1, ITGA2B, ASAP1, PXN, GOSR2, PPARG, FKBP1A, CSNK1A1, YWHAB, MAPK14, MMP9, GRB2, ITGB3, EIF4E, PRKCD, TNF, MAP3K3, CRK</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">54</td><td align="left" rowspan="1" colspan="1">MEF2A, MAP3K8, MAPK1, MAPK3, DUSP10, LNPEP, LYN, SLC3A2, EXOC7, EXOC6, EXOC1, NRAS, GSK3B, GNA13, RALB, ARRB2, VAMP3, EGF, ATF6, CEBPB, ACAP2, GOSR2, PPARG, RAB5A, YWHAZ, FKBP1A, CSNK1A1, YWHAB, YWHAH, GRB2, ITGB3, CLTA, PRKCD, MAP3K3, CTNNB1, CTNNA1, PLAUR, GNAI3, GNAQ, SOS1, RAB11A, JUNB, DDIT3, FGR, TRAF6, ASAP1, CREBBP, HBP1, MAPK14, ELK4, PAK2, EGR3, EGR2, PTPRA</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">TNF-&#x003b1;/NF-&#x003ba;B signalling</td><td align="left" rowspan="1" colspan="1">44</td><td align="left" rowspan="1" colspan="1">MEF2A, NFKBIA, SLC9A1, ASAH1, NOD2, LYN, SLC3A2, TXN, MKNK1, RALB, RELB, FADD, JUNB, DDIT3, FGR, ATF6, CASP4, CASP9, CASP7, CASP1, LIMK1, REL, CEBPB, HCK, SMPD1, KRT18, LMNB1, PPARG, NFKB2, ADAM17, FKBP1A, CSNK1A1, YWHAB, STAT1, MAPK14, MAP4K4, ERC1, EIF4E, PRKCD, CTSD, TNF, XIAP, MAP3K3, CASP10</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">MEF2A, MAP3K7, APP, MAP3K8, MAPK1, MAPK3, DUSP10, NFKBIA, ASAH1, LYN, AIFM1, SLC3A2, TXN, GSK3B, RALB, BCL10, RELB, ARRB2, EGF, ATF6, CASP4, CASP9, CASP7, CASP8, CASP1, CASP2, CYCS, CEBPB, NSMAF, LMNB1, PPARG, RAB5A, BID, YWHAZ, FKBP1A, BCL3, CSNK1A1, YWHAB, BIRC2, YWHAH, PDGFA, UBE2D3, PRKCD, MAP3K3, FBXW11, CRADD, JUNB, DDIT3, TNFAIP3, FGR, TRAF6, LIMK1, RB1, VIM, SMPD1, CREBBP, ADAM17, HBP1, STAT1, MAPK14, MAP4K3, RIPK2, ELK4, PAK2, EGR3, EGR2, CTSD, CASP10</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">TGF-&#x003b2; receptor signalling; regulation of cytoplasmic and nuclear SMAD2/3 signalling</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">MEF2A, SLC9A1, LYN, SLC3A2, TXN, PML, MKNK1, CDKN2B, RALB, JUNB, DDIT3, COL1A2, FGR, TFE3, VDR, ATF6, CDKN1A, MAX, PPP2R2A, CEBPB, HCK, LAMC1, PPARG, GADD45G, GADD45B, GADD45A, FKBP1A, ZBTB17, CSNK1A1, YWHAB, MAPK13, MAPK14, GRB2, RUNX1, EIF4E, SAP30, PRKCD, TNF, XIAP, MAP3K3, IRF7</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">MEF2A, MAP3K7, MAP3K8, MAPK1, MAPK3, DUSP10, LYN, SLC3A2, TXN, GSK3B, RALB, ARRB2, ATF6, CDKN1A, MAX, PKN1, CEBPB, PPARG, RBBP4, RAB5A, YWHAZ, FKBP1A, CSNK1A1, YWHAB, YWHAH, DYNLRB1, GRB2, PRKCD, MAP3K3, NUP153, IRF7, CTNNB1, TGFBR2, PML, PPP2CA, SOS1, PPP2CB, DAB2, JUNB, DDIT3, FGR, VDR, TRAF6, ZFYVE16, NCOA2, PPM1A, NR3C1, NEDD4L, LAMC1, CREBBP, GADD45G, GADD45B, GADD45A, HBP1, MAPK14, ELK4, SAP30, PAK2, EGR3, EGR2, PPP1R15A</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-1-mediated signalling</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">MEF2A, IL1R2, NFKBIA, IL1RN, SLC9A1, NOD2, LYN, SLC3A2, MKNK1, RALB, IL1B, RELB, JUNB, DDIT3, FGR, ATF6, CASP1, REL, CEBPB, HCK, MYD88, TOLLIP, PPARG, NFKB2, FKBP1A, CSNK1A1, YWHAB, MAPK14, ERC1, IRAK4, IRAK3, EIF4E, PRKCD, TNF, MAP3K3</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">MEF2A, MAP3K7, MAP3K8, MAPK3, DUSP10, NFKBIA, LYN, SLC3A2, GSK3B, RALB, IL1B, BCL10, RELB, ARRB2, UBE2V1, ATF6, CASP1, CEBPB, MYD88, PPARG, RAB5A, YWHAZ, FKBP1A, BCL3, CSNK1A1, YWHAB, BIRC2, YWHAH, IRAK4, IRAK3, UBE2D3, PRKCD, MAP3K3, IL1RN, FBXW11, JUNB, DDIT3, TNFAIP3, FGR, TRAF6, CREBBP, HBP1, MAPK14, RIPK2, ELK4, PAK2, EGR3, EGR2</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Chemokine signalling</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">GNG8, GNG5, PIK3CG, ROCK2, NFKBIB, NFKBIA, LYN, GNB4, PTK2B, SOS2, CXCL10, FGR, VAV1, CXCL16, CDC42, HCK, JAK2, JAK3, ADCY3, ADCY4, STAT5B, CCR2, PXN, CCR1, STAT1, STAT3, GRB2, PRKCD, CRK</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">PIK3CB, MAPK1, MAPK3, NFKBIB, NFKBIA, LYN, NRAS, GSK3B, CXCL10, ARRB2, CXCL16, CCR2, CXCL5, CCR1, GRB2, RAP1A, PRKCD, GNG5, ROCK1, NCF1, GNAI3, GNB4, GNG11, CCL28, PTK2B, SOS1, SOS2, GNG10, FGR, VAV3, CDC42, JAK2, ADCY7, ADRBK2, STAT1, STAT3, STAT2</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">p75 (NTR) signalling</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">BCL2L11, NFKBIA, NOD2, SORT1, RELB, CDC42, CASP9, CDK5, APH1B, REL, NCSTN, STAT5A, MYD88, TRPC3, RIT1, NFKB2, ADAM17, YWHAB, STAT3, MAPK14, ERC1, GRB2, DYNLT1, PRKCD, TNF, XIAP, RGS19, CRK</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">APP, MAPK1, MAPK3, NFKBIA, SORT1, NRAS, GSK3B, FRS3, BCL10, RELB, ARRB2, BEX1, CASP9, CYCS, MYD88, RIT1, YWHAZ, BCL3, YWHAB, BIRC2, YWHAH, GRB2, UBE2D3, RAP1A, PRKCD, SOS1, FBXW11, TNFAIP3, TRAF6, CDC42, APH1B, NEDD4L, GAB2, NGFRAP1, PSEN1, ADAM17, MAPK10, STAT3, MAPK14, RIPK2</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Phagosome</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">NCF4, MSR1, HLA-B, HLA-G, VAMP3, STX7, ATP6V1H, NOX3, CYBA, CYBB, CD36, TUBA4A, CTSL1, ATP6V0E1, FCGR1A, THBS1, ATP6V1E1, FCGR2A, CD14, TLR2, TLR4, TLR6, ITGB2, ITGB3, ITGAM, FCAR, TAP2, TAP1</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">HLA-DRA, HLA-B, HLA-F, VAMP3, RAB7A, HLA-DMB, CYBB, CD36, STX12, ATP6V0E1, RAB5C, FCGR3A, FCGR3B, RAB5A, FCGR1A, TUBA8, FCGR2A, CD14, ITGB3, FCAR, TUBA1A, TUBA1B, TAP2, TAP1, NCF2, NCF1, NCF4, HLA-DPA1, HLA-DPB1, MSR1, EEA1, STX7, TCIRG1, CTSL1, DYNC1I2, ATP6V1G1, ATP6V1E1, TLR2, TLR4, TLR6, ACTB</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Apoptosis</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">H1F0, BCL2L11, FADD, TNFSF10, CASP9, CASP7, LMNB1, YWHAB, PSMD12, TJP2, PSMA6, PSMA4, PSMA3, PSMB7, PSMB3, PSMB2, BMX, PSMB8, PSMB9, PSMC1, PSMD6, PSMD9, PRKCD, TNF, XIAP, CASP10</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">PIK3CB, NFKBIA, AIFM1, IL1B, CASP9, CASP7, CASP8, CYCS, MYD88, BID, BIRC2, IRAK4, IRAK3, IRAK2, FAS, TNFSF10, PRKAR1A, CSF2RB, TNFRSF10C, PPP3R1, CASP10</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Toll-like receptor signalling</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">PIK3CG, NFKBIA, CXCL10, IL1B, FADD, TRAF3, MYD88, TOLLIP, LY96, STAT1, MAPK13, MAPK14, CD14, TBK1, TLR1, TLR2, TLR4, TLR5, TLR6, TLR8, IRAK4, IFNAR1, IFNAR2, TNF, IRF7</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">MAP3K7, MAP3K8, PIK3CB, MAPK1, MAPK3, NFKBIA, CXCL10, IL1B, CASP8, MYD88, CD40, LY96, CD14, IRAK4, CD86, IRF7, TRAF6, MAPK10, STAT1, MAPK14, TBK1, TLR2, TLR4, TLR5, TLR6, TLR7, TLR8, IFNAR1, IFNAR2</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-12 mediated signalling events</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">NFKBIA, NOD2, IL1B, IL27, RELB, IL18RAP, REL, JAK2, STAT5A, NFKB2, GADD45G, GADD45B, IL18R1, STAT1, STAT3, MAPK14, SOCS1, ERC1, TNF, IL2RG, IRF1</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">HLA-DRA, NFKBIA, IL1B, BCL10, IL27, RELB, ARRB2, RAB7A, IL12RB1, IL18RAP, IL6ST, PIAS2, BCL3, BIRC2, UBE2D3, CD86, IRF1, FBXW11, TNFAIP3, TRAF6, JAK2, CREBBP, GADD45G, GADD45B, IL18R1, STAT1, STAT3, STAT2, MAPK14, SOCS1, RIPK2</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-2 mediated signalling</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">UGCG, NFKBIA, NOD2, PTK2B, RELB, REL, SMPD1, JAK3, STAT5A, STAT5B, NFKB2, STAT1, STAT3, MAPK14, SOCS3, SOCS1, ERC1, GRB2, TNF, IL2RG</td><td align="left" rowspan="1" colspan="1">0.0002</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">SGMS1, UGCG, MAPK1, MAPK3, NFKBIA, ELF1, NRAS, BCL10, RELB, ARRB2, STAM2, BCL3, BIRC2, GRB2, UBE2D3, TERT, CCNA2, PTK2B, SOS1, FBXW11, TNFAIP3, TRAF6, SMPD1, GAB2, STAT1, STAT3, MAPK14, SOCS3, SOCS1, RIPK2, HSP90AA1</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">NOD-like receptor signalling</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">NFKBIB, NFKBIA, NOD2, NLRC4, IL1B, TRIP6, CASP5, CASP1, MEFV, ERBB2IP, MAPK13, MAPK14, TNF, XIAP, PYCARD</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">MAP3K7, MAPK1, MAPK3, NFKBIB, NFKBIA, NLRC4, IL1B, CASP5, CASP8, CASP1, BIRC2, CARD6, PYCARD, TNFAIP3, TRAF6, MEFV, MAPK10, ERBB2IP, MAPK14, RIPK2, HSP90AA1</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody></table></alternatives></table-wrap><table-wrap id="pone-0054961-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0054961.t003</object-id><label>Table 3</label><caption><title>Genes downregulated in melioidosis and tuberculosis, arranged by pathway.</title></caption><alternatives><graphic id="pone-0054961-t003-3" xlink:href="pone.0054961.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">Melioidosis (total &#x0200a;=&#x0200a;1007)</td><td colspan="3" align="left" rowspan="1">Tuberculosis (total&#x0200a;=&#x0200a;1138)</td></tr><tr><td align="left" rowspan="1" colspan="1">GeneSet</td><td align="left" rowspan="1" colspan="1">Genes</td><td align="left" rowspan="1" colspan="1">List</td><td align="left" rowspan="1" colspan="1">
<italic>p</italic>-value</td><td align="left" rowspan="1" colspan="1">Genes</td><td align="left" rowspan="1" colspan="1">List</td><td align="left" rowspan="1" colspan="1">
<italic>p</italic>-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Glypican network</td><td align="left" rowspan="1" colspan="1">99</td><td align="left" rowspan="1" colspan="1">MEF2C, MAP3K4, PPP1CA, ZAP70, ATM, CARD11, PPP3CC, IL8, MEF2D, RALA, ATF2, CCM2, CDKN1B, HDAC1, CD4, NFATC3, MAF, CABIN1, WWP1, CAMK4, ETS1, AES, CTBP1, RBBP7, MAP3K14, BCL2, CD22, FYN, YWHAQ, FOXO1, FOXO4, GATA3, BLK, EIF4B, SPTBN1, CD79B, CD79A, PLEKHA2, PLEKHA1, CLTB, RANBP3, PRKCH, LEF1, UBE2I, PRKCQ, PRNP, CYTH1, CAMK2G, CYTH3, MAP3K3, PIK3R1, PTGS2, CTGF, GNG2, TGIF1, TGIF2, TCF3, RPS6, TGFBR3, MAPT, MYC, ARHGEF7, GNB1, DGKA, TBC1D4, CTLA4, RPS6KA5, PDE3B, CTDSP2, EEF2, LAT, TSC1, SGK1, LCK, NR3C1, HSPA8, CREB1, CDC25B, SNIP1, SIN3A, CD40LG, SMAD4, SMAD3, CBLB, CYLD, STRAP, MAP4K1, SRF, AXIN2, RUNX2, RUNX3, AXIN1, ITK, PTPN6, MALT1, PLCG1, AKT1, GSC, PTPRC</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">105</td><td align="left" rowspan="1" colspan="1">HRAS, PPP2R5D, MAP3K7, MAP3K4, ZAP70, ATM, EEF2K, CARD11, PPP3CB, PPP3CC, IL4, MEF2D, DUSP8, IL10, RALA, ARFGAP1, MAPKAPK5, HDAC2, CDKN1B, HDAC1, IKBKB, PPP2R2A, CD4, NFATC3, MAF, CABIN1, WWP1, TGFBRAP1, CD72, ETS1, AES, CTBP1, RBBP4, RBBP7, MAP3K14, BCL2, CD22, CD19, FYN, FOXO1, FOXO3, GATA3, BLK, EIF3A, CD79B, CD79A, SHC1, PRKCA, LEF1, PRKCH, UBE2I, PRKCQ, CYTH1, CAMK2G, MAP3K1, YES1, IRF4, IBTK, TGFBR2, RPS6, TGFBR3, MYC, ARHGEF7, TLE1, GNB1, TBC1D4, CTLA4, RPS6KA5, XPO1, RPS6KB1, CTDSP1, CTDSP2, EEF2, TRAF2, LAT, TSC1, TSC2, SGK1, CDK4, LCK, INPP5D, HSPA8, CREB1, SIN3B, SIN3A, CD40LG, MACF1, SMAD7, SMAD3, DCP1A, CYLD, FZD3, MAPK13, CALM1, MAP4K1, AXIN2, RUNX2, RUNX3, AXIN1, ITK, MALT1, PLCG1, AKT1, PAK2, CSK</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein synthesis, RNA translation, ribosome</td><td align="left" rowspan="1" colspan="1">85</td><td align="left" rowspan="1" colspan="1">RPLP2, RPLP0, RPLP1, PABPC1, EIF4A2, EEF1G, EEF1D, RPS27A, RPL35A, RPL10A, DOHH, RPL37A, RPL13A, CCT3, CCT7, RPL18A, EIF5A, EEF1B2, EIF3D, EIF3B, EIF3G, EIF3H, EIF3E, EIF3F, EIF3K, EEF1A1, EIF4B, EIF4H, DHPS, GSPT2, RPL18, RPL17, RPL19, RPL14, RPL13, RPL15, RPL10, RPL11, RPL12, EIF2S3, RPS18, RPS19, RPS16, RPS14, RPS15, RPS12, RPS13, RPS10, RPS11, RPS25, RPS27, RPS28, RPS29, RPS20, RPS23, RPS6, RPS5, RPL35, RPL36, RPL38, RPL30, RPL32, RPL27, RPL29, RPL22, DPM2, EIF5, EEF2, UBA52, RPL7, RPL6, RPL8, RPL3, RPL5, RPL4, RPL7A, RPL23A, RPS2, RPS3, RPS4X, RPS15A, RPL27A, EIF2B1, PIGA, PIGP</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">CCT2, CCT3, CCT6A, CCT7, EEF1B2, EEF1D, EEF1G, EEF2, EIF1AX, EIF2B1, EIF2B4, EIF2B5, EIF2S3, EIF3A, EIF3B, EIF3D, EIF3F, EIF3G, EIF3H, EIF3I, EIF3K, EIF4A2, FBXW7, PABPC1, RPL10, RPL10A, RPL11, RPL13, RPL13A, RPL14, RPL15, RPL18, RPL19, RPL22, RPL23, RPL23A, RPL26, RPL27, RPL29, RPL3, RPL31, RPL32, RPL35, RPL36, RPL36A, RPL37A, RPL4, RPL5, RPL6, RPL7, RPL7A, RPL8, RPL9, RPLP0, RPLP1, RPLP2, RPS11, RPS13, RPS15, RPS15A, RPS16, RPS18, RPS19, RPS2, RPS20, RPS23, RPS24, RPS25, RPS27, RPS27A, RPS28, RPS29, RPS3, RPS3A, RPS4X, RPS5, RPS6, RPS7, RPS9, UBA52</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">TGF-&#x003b2; receptor signalling,regulation of SMAD2/3</td><td align="left" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1">MEF2C, MAP3K4, PPP1CA, ATM, IL8, MEF2D, RALA, ATF2, CCM2, HDAC1, NFATC3, MAF, CABIN1, WWP1, CAMK4, CTBP1, RBBP7, BCL2, FYN, YWHAQ, FOXO1, FOXO4, GATA3, BLK, SPTBN1, PRKCH, UBE2I, PRKCQ, MAP3K3, PTGS2, CTGF, TGIF1, TGIF2, TCF3, TGFBR3, MAPT, MYC, DGKA, CTLA4, RPS6KA5, CTDSP2, LCK, NR3C1, HSPA8, CREB1, CDC25B, SNIP1, SIN3A, CD40LG, SMAD4, SMAD3, CBLB, STRAP, SRF, RUNX2, RUNX3, AXIN1, GSC, TGFB3, FNTA, E2F4, ANAPC1, ANAPC5, ETS1, SNW1, LEF1, CAMK2G, PIK3R1, PIK3R2, FOSB, RBL2, JUND, CTCF, CDC23, GIPC1, AXIN2</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">MAP3K7, MAP3K4, ATM, EEF2K, IL4, MEF2D, DUSP8, IL10, RALA, MAPKAPK5, HDAC2, HDAC1, PPP2R2A, NFATC3, MAF, CABIN1, WWP1, TGFBRAP1, CTBP1, RBBP4, RBBP7, BCL2, FYN, FOXO1, FOXO3, GATA3, BLK, SHC1, PRKCA, PRKCH, UBE2I, PRKCQ, MAP3K1, YES1, IRF4, TGFBR2, TGFBR3, MYC, CTLA4, RPS6KA5, RPS6KB1, CTDSP1, CTDSP2, TRAF2, TSC2, CDK4, LCK, HSPA8, CREB1, SIN3B, SIN3A, CD40LG, SMAD7, SMAD3, DCP1A, MAPK13, CALM1, RUNX2, RUNX3, AXIN1, PAK2</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">IFN-&#x003b3; pathway</td><td align="left" rowspan="1" colspan="1">72</td><td align="left" rowspan="1" colspan="1">MEF2C, MAP3K4, PPP1CA, ATM, DOK2, IL8, MEF2D, RALA, ATF2, CCM2, HDAC1, NFATC3, MAF, CABIN1, WWP1, CAMK4, ETS1, CTBP1, RBBP7, BCL2, FYN, YWHAQ, FOXO1, FOXO4, GATA3, BLK, EIF4B, SPTBN1, PRKCH, UBE2I, PRKCQ, CAMK2G, MAP3K3, PIK3R1, PTGS2, CTGF, TGIF1, TGIF2, TCF3, RPS6, TGFBR3, MAPT, MYC, DGKA, CTLA4, RPS6KA5, CTDSP2, EEF2, TSC1, LCK, NR3C1, HSPA8, CREB1, CDC25B, JAK1, SNIP1, SIN3A, RAPGEF1, CD40LG, FCER2, SMAD4, SMAD3, PTPN11, CBLB, STRAP, SRF, RUNX2, RUNX3, AXIN1, PTPN6, AKT1, GSC</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">82</td><td align="left" rowspan="1" colspan="1">PPP2R5D, MAP3K7, MAP3K4, ATM, EEF2K, DOK2, IL4, MEF2D, DUSP8, IL10, RALA, MAPKAPK5, TFF3, HDAC2, HDAC1, PPP2R2A, NFATC3, MAF, CABIN1, WWP1, TGFBRAP1, PIAS1, ETS1, CTBP1, RBBP4, RBBP7, MAP3K11, BCL2, FYN, FOXO1, FOXO3, GATA3, BLK, EIF3A, SHC1, PRKCA, PRKCH, UBE2I, PRKCQ, CAMK2G, MAP3K1, YES1, IRF4, TGFBR2, RPS6, TGFBR3, MYB, MYC, CTLA4, RPS6KA5, RPS6KB1, CTDSP1, CTDSP2, EEF2, TRAF2, TSC1, TSC2, CDK4, HMGA1, LCK, INPP5D, HSPA8, CREB1, SIN3B, SIN3A, RAPGEF1, CD40LG, FCER2, SMAD7, SMAD3, PTPN11, DCP1A, GTF3A, STAT6, MAPK13, CALM1, RUNX2, RUNX3, AXIN1, AKT1, PAK2, LTA</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">TRAIL (TNF superfamily, member 10) signalling</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">ZAP70, ATM, PARP1, CARD11, PPP3CC, IL8, LMNA, MEF2D, CDKN1B, CASP8, CASP2, CYCS, CD4, NFATC3, MAF, CABIN1, CAMK4, ETS1, MAP3K14, PRF1, BCL2, CD22, FYN, YWHAQ, FOXO1, FOXO4, GATA3, BLK, EIF4B, CD79B, CD79A, PLEKHA2, PLEKHA1, CLTB, PRKCH, PRKCQ, CFL2, CYTH1, CAMK2G, CYTH3, PIK3R1, PTGS2, RPS6, MYC, ARHGEF7, DGKA, NUMA1, TBC1D4, CTLA4, PDE3B, EEF2, TRADD, LAT, TSC1, SGK1, LCK, CD40LG, CBLB, CYLD, SATB1, MADD, MAP4K1, ITK, PTPN6, MALT1, PLCG1, DAP3, AKT1, PTPRC, SPTAN1</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">83</td><td align="left" rowspan="1" colspan="1">HRAS, PPP2R5D, MAP3K7, ZAP70, ATM, PARP1, AIFM1, CARD11, PPP3CB, PPP3CC, IL4, MEF2D, DFFA, DFFB, TFAP2A, ARFGAP1, CDKN1B, IKBKB, LRDD, CYCS, CD4, NFATC3, MAF, CABIN1, KRT18, CD72, ETS1, MAP3K14, PRF1, BCL2, CD22, BIRC3, CD19, FYN, FOXO1, FOXO3, GATA3, BLK, EIF3A, CD79B, CD79A, SHC1, PRKCA, PRKCH, PRKCQ, CYTH1, CAMK2G, MAP3K1, YES1, IRF4, IBTK, RPS6, MYC, ARHGEF7, NUMA1, TBC1D4, CTLA4, XPO1, RPS6KB1, EEF2, TRAF2, TRADD, LAT, TSC1, TSC2, SGK1, CDK4, LCK, INPP5D, SMPD1, CD40LG, TNFRSF10B, CYLD, CALM1, SATB1, MAP4K1, ITK, MALT1, PLCG1, DAP3, AKT1, CSK, SPTAN1</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Class I PI3K signalling events</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">ZAP70, ATM, CARD11, PPP3CC, IL8, MEF2D, CDKN1B, CD4, NFATC3, MAF, CABIN1, CAMK4, ETS1, MAP3K14, BCL2, CD22, FYN, YWHAQ, FOXO1, FOXO4, GATA3, BLK, EIF4B, CD79B, CD79A, PLEKHA2, PLEKHA1, CLTB, PRKCH, PRKCQ, CYTH1, CAMK2G, CYTH3, PIK3R1, PTGS2, RPS6, ARHGEF7, DGKA, TBC1D4, CTLA4, PDE3B, EEF2, LAT, TSC1, SGK1, LCK, CD40LG, CBLB, CYLD, MAP4K1, ITK, PTPN6, MALT1, PLCG1, AKT1, PTPRC</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">HRAS, PPP2R5D, MAP3K7, ZAP70, ATM, CARD11, PPP3CB, PPP3CC, IL4, MEF2D, ARFGAP1, CDKN1B, IKBKB, CD4, NFATC3, MAF, CABIN1, CD72, ETS1, MAP3K14, BCL2, CD22, CD19, FYN, FOXO1, FOXO3, GATA3, BLK, EIF3A, CD79B, CD79A, SHC1, PRKCA, PRKCH, PRKCQ, CYTH1, CAMK2G, MAP3K1, YES1, IRF4, IBTK, RPS6, ARHGEF7, TBC1D4, CTLA4, XPO1, RPS6KB1, EEF2, LAT, TSC1, TSC2, SGK1, CDK4, LCK, INPP5D, CD40LG, CYLD, CALM1, MAP4K1, ITK, MALT1, PLCG1, AKT1, CSK</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">TNF- &#x003b1;/NF-&#x003ba;B</td><td align="left" rowspan="1" colspan="1">51</td><td align="left" rowspan="1" colspan="1">MEF2C, ATM, PARP1, IL8, LMNA, MEF2D, RALA, ATF2, CCM2, CASP8, CASP2, CYCS, NFATC3, MAF, CABIN1, CAMK4, GNB2L1, MAP3K14, PRF1, BCL2, FYN, YWHAQ, GATA3, BLK, PRKCH, PRKCQ, CFL2, MAP3K3, PIK3R1, PTGS2, TCF3, MYC, DGKA, NUMA1, CTLA4, RPS6KA5, TRADD, LCK, CREB1, CDC25B, CD40LG, CBLB, CYLD, SATB1, MADD, MAP4K5, MAP4K2, SRF, MALT1, AKT1, SPTAN1</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">SMARCA4, SMARCB1, IKBKE, HDAC2, HDAC1, IKBKB, FAF1, MAP3K14, BIRC3, AKAP8, MAP3K2, MAP2K5, RPS13, BTRC, RPS6KB1, LRPPRC, TRAF1, TRAF2, RPL6, RPL4, TRAF5, TRADD, FBL, PTPN11, POLR1C, POLR2H, HSP90AB1, AKT1, MCM7, PSMD1, MCM5, KPNA6, PEBP1, KPNA3</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Formation and maturation of mRNA transcript</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">PTBP1, DHX9, YBX1, SF3B4, SF3B3, SF3A2, SF3A1, SF3A3, HNRNPUL1, TXNL4A, NCBP2, SNRPD3, DNAJC8, PRPF6, SNRNP200, PRPF8, HNRNPA0, TH1L, PCBP1, PCBP2, ERCC3, LSM2, NHP2L1, GTF2H3, TCEA1, RNMT, RBM5, SNRPA1, HNRNPR, HNRNPU, HNRNPM, HNRNPK, HNRNPD, HNRNPC, TAF4, RBMX, HNRNPH1, CPSF1, U2AF2, CCNT2, SNRNP40, POLR2H, POLR2G, SNRNP70, SRRM1, SNRPB, RNPS1</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">49</td><td align="left" rowspan="1" colspan="1">TAF4B, PTBP1, SF3B4, SF3B3, SF3B1, SF3A2, SF3A1, SF3A3, HNRNPUL1, NCBP2, DNAJC8, PRPF4, SNRNP200, PRPF8, HNRNPA1, SUPT16H, TH1L, ERCC3, ERCC2, LSM2, NHP2L1, GTF2H1, RNMT, RBM5, DDX23, SNRPA1, HNRNPU, HNRNPM, METTL3, HNRNPD, TAF4, TAF6, HNRNPH1, COBRA1, CPSF1, SUPT5H, RNGTT, POLR2H, POLR2G, POLR2F, POLR2I, POLR2A, SNRNP70, SRRM1, EFTUD2, SNRPB, SNRPA, RNPS1, SMC1A</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Spliceosome</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">THOC3, THOC1, SF3B4, SF3B3, SF3A2, SF3A1, SF3A3, TXNL4A, NCBP2, SNRPD3, PRPF3, PRPF6, SNRNP200, PRPF8, DDX5, SNW1, PPIE, PUF60, PCBP1, LSM4, LSM2, NHP2L1, SNRPA1, HNRNPU, HNRNPM, HNRNPK, TCERG1, DDX46, HNRNPC, RBMX, WBP11, HSPA8, U2AF2, SNRNP40, SNRNP70, RBM17, SNRPB</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">XAB2, THOC2, THOC1, SF3B4, SF3B3, SF3B1, DHX15, DHX16, SF3A2, SF3A1, SF3A3, NCBP2, PRPF3, PRPF4, SNRNP200, PRPF8, DDX5, HNRNPA1, PPIH, PUF60, LSM7, LSM5, LSM4, LSM2, NHP2L1, HSPA1A, DDX23, SNRPA1, HNRNPU, HNRNPM, DDX42, HSPA8, SNRNP70, RBM25, RBM17, EFTUD2, SNRPB, SNRPA, SNRPC</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">T-cell receptor signalling</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">ZAP70, CARD11, PPP3CC, ICOS, CD4, NFATC3, CD3G, CD3D, CD3E, MAP3K14, CD28, FYN, CD8A, CD8B, PRKCQ, PIK3R1, PIK3R2, CTLA4, LAT, LCK, CD40LG, CBLB, ITK, PTPN6, MALT1, PLCG1, AKT1, PAK4, CD247, PTPRC, HLA-DOA, HLA-DOB, RPS27A, HLA-DPA1</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">HRAS, MAP3K7, ZAP70, ATM, CARD11, IL4, IKBKB, CD4, NFATC3, CABIN1, CD3D, CD3E, MAP3K14, CD28, FYN, SHC1, PRKCA, PRKCQ, MAP3K1, XPO1, STK39, LAT, LCK, INPP5D, CD40LG, PTPN11, CYLD, CALM1, MAP4K1, PTPN7, ITK, MALT1, PLCG1, AKT1, CSK, CD247, RASGRP1, RASGRP2</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-2-mediated signalling events</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">ATM, DOK2, IKZF3, MAP3K14, PRF1, BCL2, FYN, PIK3R1, IL2RB, RPS6, MYC, CCND2, LCK, JAK1, PTPN11, CYLD, MALT1, AKT1</td><td align="left" rowspan="1" colspan="1">0.022</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">HRAS, ATM, DOK2, IL4, IKBKB, MAP3K14, PRF1, BCL2, FYN, FOXO3, EIF3A, SHC1, PRKCA, IL2RB, RPS6, MYB, MYC, CCND2, XPO1, RPS6KB1, CDK6, LCK, SMPD1, PTPN11, CYLD, CISH, CALM1, MALT1, AKT1, LTA</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label/><p>IFN&#x0200a;=&#x0200a;interferon, IGF&#x0200a;=&#x0200a;insulin-like growth factor, IL&#x0200a;=&#x0200a;interleukin, NF-&#x003ba;B&#x0200a;=&#x0200a;nuclear factor kappa-light-chain-enhancer of activated B cells, PI3K&#x0200a;=&#x0200a;phosphoinositide 3-kinase, RNA&#x0200a;=&#x0200a;ribonucleic acid, TGF&#x0200a;=&#x0200a;transforming growth factor, TNF&#x0200a;=&#x0200a;tumour necrosis factor.</p></fn><fn id="nt104"><label/><p>Note:&#x02013; Genes names are those assigned by the HUGO gene nomenclature committee.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0054961-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0054961.t004</object-id><label>Table 4</label><caption><title>Interferon signatures for melioidosis and tuberculosis.</title></caption><alternatives><graphic id="pone-0054961-t004-4" xlink:href="pone.0054961.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="3" align="left" rowspan="1">Melioidosis</td><td colspan="3" align="left" rowspan="1">Tuberculosis</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Type 1</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>Both</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>Type 2</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>Type 1</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>Both</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>Type 2</italic>
</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">AIM2CTSASH3GLB1TCN2NEU1FCGR1AH2AFJIFITM3LACTBDYSFVNN1PGS1CXCL16</td><td align="left" rowspan="1" colspan="1">TLR5GYG1DUSP3CASP1IFITM1UPP1SERPING1VAMP5SOCS3SAT1SLC30A1JAG1LIMK2DYNLT1TXNMYD88TAP1JAK2IL15</td><td align="left" rowspan="1" colspan="1">TNFSF10DRAMNEUR1CASP5SEPT4CD274SYN2H4HIST2H4BRAB24</td><td align="left" rowspan="1" colspan="1">GBP5ANKRD22FCGR1AAIM2CEACAM1WDFY1EPSTI1LY96GADD45BLACTBSP140SERTAD3SH3GLB1</td><td align="left" rowspan="1" colspan="1">CASP1DUSP3GBP1GBP2GBP4IL15ATF3PSME1PSME2UBE2L6GSTO1GCH1TAP1TRIM22STAT1TAP2PSMB8VAMP5WARSSECTM1GYG1SERPING1IRF1SAT1RTP4CLIC1CASP4PLAURDYNLT1SLC30A1ACTA2</td><td align="left" rowspan="1" colspan="1">SEPT4CD274NLRC5PSMB10P2RY14RNF213</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt105"><label/><p>Note: The interferon signatures for melioidosis (<bold>A</bold>) and tuberculosis (<bold>B</bold>) are listed here (analysis from <ext-link ext-link-type="uri" xlink:href="http://www.interferome.org">www.interferome.org</ext-link>). Berry <italic>et al.</italic> noted that both type 1 and type 2 interferon responses were prominent in tuberculosis. We find that type 1 interferon responses appear in melioidosis also.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Modular Analysis</title><p>In a modular analysis of the upregulated genes (<xref ref-type="fig" rid="pone-0054961-g002">Figure 2A</xref>), interferon and cytokine signalling clustered together in the centre of the network, causing the complement (cluster 1), NOD-like receptor (cluster 2) and TLR (cluster 3) pathways to gain prominence. In the downregulated genes (<xref ref-type="fig" rid="pone-0054961-g002">Figure 2B</xref>), the most prominent clusters were the ribosomal proteins (cluster 1) and zinc finger proteins (cluster 2).</p><fig id="pone-0054961-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0054961.g002</object-id><label>Figure 2</label><caption><title>Network representation of genes differentially expressed in melioidosis.</title><p>&#x02018;Canonical&#x02019; pathways (such as those presented in a standard biochemistry textbook) are manually curated collections of protein interactions arranged in a manner that aids human understanding, and as artificial constructs the boundaries between pathways are subjective. Pathways that are conceptually distinct often have proteins in common and overlap, so in modular analysis, multiple pathways may collapse into a single module, causing other pathways and relationships to gain prominence. These two networks (<bold>A</bold> and <bold>B</bold>) represent those genes that are differentially expressed in melioidosis. For simplicity of presentation, we have used only a subset of genes in these networks. The top 221 upregulated genes (as ranked by <italic>p</italic>-value) are presented in <bold>A</bold>, and the top 155 downregulated genes are in <bold>B</bold>. The same clusters were found in an analysis of the whole gene set and those results are presented in <xref ref-type="table" rid="pone-0054961-t002">Tables 2</xref> &#x00026; <xref ref-type="table" rid="pone-0054961-t003">3</xref>. <bold>Network</bold>
<bold>A</bold>. IFN-&#x003b3;, TNF-&#x003b1;, IL-12 signalling pathways cluster together with the glypican network in the centre of the graph, but the complement/chemokine receptor (<bold>cluster 1</bold>), inflammasome (<bold>cluster 2</bold>) and Toll-like receptor pathways come to prominence in this analysis (<bold>cluster 3</bold>). <bold>Network B</bold>. IFN-&#x003b3;, TGF-&#x003b2; and TNF signalling again cluster in the middle of the network. The two most prominent clusters are ribosomal proteins (<bold>cluster 1</bold>) and zinc finger proteins (<bold>cluster 2</bold>).</p></caption><graphic xlink:href="pone.0054961.g002"/></fig></sec><sec id="s3c"><title>PAMP-specific Responses</title><p>
<italic>B. pseudomallei</italic> expresses lipopolysaccharide on its outer membrane, while <italic>M. tuberculosis</italic> does not and has a lipid-rich cell wall. Lipopolysaccharide is recognized by TLR4 and CD14, and both are upregulated in melioidosis (<italic>P</italic>&#x0200a;=&#x0200a;0.0016 and 1.5 &#x000d7; 10<sup>&#x02013;6</sup>, respectively); however, TLR4 and CD14 are also upregulated in tuberculosis (<italic>P</italic>&#x0200a;=&#x0200a;1.5 &#x000d7; 10<sup>&#x02013;6</sup> and 9.4 &#x000d7; 10<sup>&#x02013;4</sup>). <italic>B. pseudomallei</italic> is a flagellated, motile bacterium, while <italic>M. tuberculosis</italic> is immotile with no flagellum. Flagellin is a ligand for TLR5 <xref rid="pone.0054961-Hayashi1" ref-type="bibr">[25]</xref> and NLRC4 <xref rid="pone.0054961-Sutterwala1" ref-type="bibr">[26]</xref>. Both TLR5 and NLRC4 were upregulated in melioidosis (<italic>P</italic>&#x0200a;=&#x0200a;5.4 &#x000d7; 10<sup>&#x02013;13</sup> and 4.2 &#x000d7; 10<sup>&#x02013;10</sup>, respectively), but both were upregulated in tuberculosis also (<italic>P</italic>&#x0200a;=&#x0200a;8.1 &#x000d7; 10<sup>&#x02013;10</sup> and 2.4 &#x000d7; 10<sup>&#x02013;11</sup>).</p></sec></sec><sec id="s4"><title>Discussion</title><p>There were 4632 genes differentially expressed in melioidosis and 5045 genes in tuberculosis, thus approximately 20% of the human genome is differentially regulated in each disease. The most prominent pathway in melioidosis was interferon (IFN)-&#x003b3; and the same was true of tuberculosis. There were no pathways differentially regulated in melioidosis that were not also differentially regulated in tuberculosis, and there was no signature which reliably distinguished melioidosis and tuberculosis.</p><p>Berry <italic>et al.</italic> identified an 86-gene signature as being specific for tuberculosis after eliminating differentially regulated genes common to <italic>Streptococcus pyogenes</italic> and <italic>Staphylococcus aureus</italic> infections, and to two auto-inflammatory diseases (systemic lupus erythematosus and Still&#x02019;s disease). This signature was also present in melioidosis, which is surprising given that all melioidosis patients recruited had acute rather than chronic melioidosis, which is clinically distinct from tuberculosis.</p><sec id="s4a"><title>Interferon-mediated Responses</title><p>The IFN-&#x003b3; pathway was reported as the most prominent pathway identified in gene expression studies of a mouse model of melioidosis <xref rid="pone.0054961-Chin1" ref-type="bibr">[27]</xref>, and blocking IFN-&#x003b3; dramatically increases host susceptibility to melioidosis <xref rid="pone.0054961-Wiersinga1" ref-type="bibr">[3]</xref>. In human studies, plasma IFN-&#x003b3; concentrations were high in melioidosis <xref rid="pone.0054961-Wiersinga1" ref-type="bibr">[3]</xref>, and IFN-&#x003b3;-mediated responses were also the most prominent feature in a gene expression study of melioidosis in another human cohort <xref rid="pone.0054961-Pankla1" ref-type="bibr">[28]</xref>. The finding here that this feature is shared with tuberculosis is unsurprising, because IFN-&#x003b3; responses are crucial for the host response against intracellular pathogens such as <italic>B. pseudomallei</italic> and <italic>M. tuberculosis</italic>. IFN-&#x003b3; treatment has a role in the management of multidrug-resistant tuberculosis, and adjunctive therapy with IFN-&#x003b3; is beneficial in a mouse model of melioidosis <xref rid="pone.0054961-Propst1" ref-type="bibr">[29]</xref>, although its role in clinical melioidosis remains undefined <xref rid="pone.0054961-Koh2" ref-type="bibr">[30]</xref>.</p><p>In their original report on this tuberculosis cohort, Berry <italic>et al.</italic> noted that type 2 IFN-&#x003b3; responses were prominent, but noted that type 1 IFN-&#x003b1;&#x003b2; responses were present also <xref rid="pone.0054961-Berry1" ref-type="bibr">[7]</xref>. We found that type 1 interferon-&#x003b1;&#x003b2; responses were just as prominent in melioidosis, but the clinical relevance of this remains to be defined.</p><p>Type 1 interferons can be produced by almost any cell type (leukocytes, fibroblasts and endothelial cells) and are induced by a range of bacterial pathogens, whereupon they proceed to modulate the host response in a manner that is as yet incompletely understood <xref rid="pone.0054961-GonzlezNavajas1" ref-type="bibr">[31]</xref>. The signalling pathways initiated by type 1 interferons are best described in terms of their activation of signal transducer and activator of transcription (STAT) family members (STAT1 to STAT6) <xref rid="pone.0054961-Hebenstreit1" ref-type="bibr">[32]</xref>, the best studied of which are STAT1 and STAT3. STAT1 activation is dependent on both type 1 and type 2 interferons and results in a pro-inflammatory response, with recruitment of inflammatory cells and the enhancement of antigen presentation <xref rid="pone.0054961-GonzlezNavajas1" ref-type="bibr">[31]</xref>. On the other hand, STAT3 activation is a key mediator of IL-10 signalling, and results in inhibition of inflammatory responses and directly inhibits STAT1 activation <xref rid="pone.0054961-GonzlezNavajas1" ref-type="bibr">[31]</xref>. The role of STAT4 is less well described, but STAT4 activation may play a role in T helper 1 lymphocyte differentiation, which is an essential part of the host response to intracellular pathogens. Type 1 interferons are also necessary for the production of inducible nitric oxide synthase <xref rid="pone.0054961-Utaisincharoen1" ref-type="bibr">[33]</xref>, which is in turn necessary for the clearance of intracellular bacteria. Interestingly, type 1 interferons are able to inhibit IL-1&#x003b2; production and inflammasome assembly by two separate mechanisms: the first is via inhibition of NLRP1 and NLRP3 inflammasomes in a STAT1-dependent manner; the second, is a reduction in pro-IL-1 levels via a STAT3-dependent pathway <xref rid="pone.0054961-Guarda1" ref-type="bibr">[34]</xref>. It has previously be shown that host response to <italic>B. pseudomallei</italic> is inflammasome-dependent <xref rid="pone.0054961-Breitbach1" ref-type="bibr">[35]</xref>.</p><p>The role of type 1 interferons in tuberculosis is unclear, since mice deficient in the production of type 1 interferons are better able to control <italic>M. tuberculosis</italic> infections <xref rid="pone.0054961-Stanley1" ref-type="bibr">[36]</xref>, but type 1 interferons also play a non-redundant protective role in the absence of type 2 interferon signaling <xref rid="pone.0054961-Desvignes1" ref-type="bibr">[37]</xref>. The role of type 1 interferons in the pathogenesis of melioidosis remains to be studied.</p></sec><sec id="s4b"><title>PAMP-specific Responses</title><p>TLR4 and CD14 are upregulated in both melioidosis and tuberculosis. The classical ligand for TLR4 <xref rid="pone.0054961-Qureshi1" ref-type="bibr">[38]</xref> and for CD14 <xref rid="pone.0054961-Kitchens1" ref-type="bibr">[39]</xref> is lipopolysaccharide (LPS), which would explain this finding for <italic>B. pseudomallei</italic>. TLR4 will recognize heparin-binding haemagglutinin <xref rid="pone.0054961-Jung1" ref-type="bibr">[40]</xref>, and CD14 will bind lipoarabinomannan <xref rid="pone.0054961-Pugin1" ref-type="bibr">[41]</xref>, both of which are expressed by <italic>M. tuberculosis</italic>.</p><p>The pattern recognition receptors TLR5 <xref rid="pone.0054961-Hayashi1" ref-type="bibr">[25]</xref> and NLRC4 <xref rid="pone.0054961-Sutterwala1" ref-type="bibr">[26]</xref> both recognize flagellin. No alternative ligand has yet been described for TLR5, so it is more difficult to explain why tuberculosis should apparently induce a flagellin-response. One explanation is that upregulation of pattern recognition receptors is not driven by their ligands. TLR5 expression is induced as part of the type 1 interferon response <xref rid="pone.0054961-Khoo1" ref-type="bibr">[42]</xref>, while NLRC4 is upregulated as part of the TNF-&#x003b1; response <xref rid="pone.0054961-Gutierrez1" ref-type="bibr">[43]</xref>. Both pathways are prominent in the host response to melioidosis. In support of this hypothesis, the TLRs are upregulated as a group in both melioidosis (TLR1, TLR2, TLR4, TLR5, TLR6, TLR8 and TLR10) and tuberculosis (TLR2, TLR4, TLR5, TLR6, TLR7, TLR8).</p></sec><sec id="s4c"><title>Limitations and Future Research</title><p>Tuberculosis is strongly associated with HIV infection, but melioidosis is not. HIV targets primarily CD4-positive T-lymphocytes and lymphocyte depletion is a feature of all sepsis. Lymphocytes were depleted in both the melioidosis and the TB cohorts, so lymphocyte-related pathways and modules are missing from the whole blood gene expression data of both cohorts, making it difficult to make any comment about the relative role of CD4-positive cells in melioidosis compared to tuberculosis. The whole blood signature was dominated by neutrophils which may also have obscured any lymphocyte signature. Future studies that use purified lymphocytes harvested from melioidosis patients may shed light on this issue.</p><p>Microarrays generate large amounts of data that are useful for the development of hypotheses. Our analysis has identified a number of other pathways that are differentially regulated in melioidosis, but which are unstudied to date. Notably, the TRAIL pathway is differentially regulated in melioidosis, but its role remains undefined at present. The glypicans (cell surface proteoglycans) contribute to cell proliferation and growth, both essential processes in the host response to infection. To date, investigations into the role of glypicans have been confined primarily to cancer biology, although glypican-deficient mice are more susceptibility to respiratory infections <xref rid="pone.0054961-CanoGauci1" ref-type="bibr">[44]</xref>. In tuberculosis, the glypican network appears to have greater prominence than even the interferon-mediated responses.</p></sec><sec id="s4d"><title>Conclusions</title><p>Host responses to melioidosis and TB are dominated by interferon-signalling events, despite the fact that the organisms are unrelated and present completely different cell-surface PAMPs to the host. This is likely because they both stimulate host responses common to intracellular pathogens, and because the expression of pattern recognition receptors is not driven by their ligands, but by cytokine responses (primarily IFN-&#x003b3; and TNF-&#x003b1;). The 86-gene signature identified by Berry <italic>et al.</italic> clusters melioidosis patients just as effectively as it clusters tuberculosis. It therefore seems likely that whole blood gene signatures will not be able to diagnose tuberculosis in areas where melioidosis and TB are co-endemic, but may find utility when interpreted in combination with clinical features. Further studies using direct comparisons will be required to confirm this finding.</p></sec></sec>